Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tyler Stewart

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Medrxiv : the Preprint Server for Health Sciences|May 7, 2026
Androgen Deprivation Therapy (ADT) and Radiotherapy (RT) with Imaging Evaluation Longitudinally (ARIEL) trial: protocol, early results, and implications of neoadjuvant ADT for focal RT boost in prostate cancerYuze Song, Mariluz Rojo Domingo, Lily Nguyen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 15, 2026
Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In OncologyThomas W Flaig, Philippe E Spiess, Michael Abern, et al.
Clinical Genitourinary Cancer|July 6, 2023
Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" ExperienceDimitra Rafailia Bakaloudi, Rafee Talukder, Genevieve Ihsiu Lin, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 16, 2024
NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024Thomas W Flaig, Philippe E Spiess, Michael Abern, et al.
European Urology Oncology|January 11, 2021
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint InhibitorsAli Raza Khaki, Ang Li, Leonidas N Diamantopoulos, et al.
Nature|October 9, 2024
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsFerdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, et al.
Nature|February 27, 2025
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsFerdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Medrxiv : the Preprint Server for Health Sciences|May 7, 2026
Androgen Deprivation Therapy (ADT) and Radiotherapy (RT) with Imaging Evaluation Longitudinally (ARIEL) trial: protocol, early results, and implications of neoadjuvant ADT for focal RT boost in prostate cancerYuze Song, Mariluz Rojo Domingo, Lily Nguyen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 15, 2026
Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In OncologyThomas W Flaig, Philippe E Spiess, Michael Abern, et al.
Clinical Genitourinary Cancer|July 6, 2023
Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" ExperienceDimitra Rafailia Bakaloudi, Rafee Talukder, Genevieve Ihsiu Lin, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 16, 2024
NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024Thomas W Flaig, Philippe E Spiess, Michael Abern, et al.
European Urology Oncology|January 11, 2021
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint InhibitorsAli Raza Khaki, Ang Li, Leonidas N Diamantopoulos, et al.
Nature|October 9, 2024
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsFerdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, et al.
Nature|February 27, 2025
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsFerdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, et al.
Pageof 4